172 related articles for article (PubMed ID: 19755674)
21. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
[TBL] [Abstract][Full Text] [Related]
22. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
[TBL] [Abstract][Full Text] [Related]
23. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
[TBL] [Abstract][Full Text] [Related]
24. Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma.
Mateo G; Corral M; Almeida J; López-Berges C; Nieto mJ; García-Marcos A; Vázquez L; del Cañizo C; Orfao A; San Miguel JF
Haematologica; 2003 Sep; 88(9):1013-21. PubMed ID: 12969809
[TBL] [Abstract][Full Text] [Related]
25. Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival.
An G; Wang H; Qin X; Shi L; Xu Y; Deng S; Sui W; Zhu G; Yao H; Yi S; Qin Y; Li F; Hao M; Ru K; Qi J; Cheng T; Wang J; Chang H; Qiu L
Leuk Res; 2014 Jun; 38(6):666-72. PubMed ID: 24746293
[TBL] [Abstract][Full Text] [Related]
26. Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Leuk Lymphoma; 2017 Feb; 58(2):308-315. PubMed ID: 27390076
[TBL] [Abstract][Full Text] [Related]
27. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.
Peceliunas V; Janiulioniene A; Matuzeviciene R; Griskevicius L
Cytometry B Clin Cytom; 2011 Sep; 80(5):318-23. PubMed ID: 21634008
[TBL] [Abstract][Full Text] [Related]
28. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
[TBL] [Abstract][Full Text] [Related]
30. Plasma cell maturity as a predictor of prognosis in multiple myeloma.
Iriyama N; Miura K; Hatta Y; Uchino Y; Kurita D; Takahashi H; Sakagami H; Sakagami M; Kobayashi Y; Nakagawa M; Ohtake S; Iizuka Y; Takei M
Med Oncol; 2016 Aug; 33(8):87. PubMed ID: 27383407
[TBL] [Abstract][Full Text] [Related]
31. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
32. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
[TBL] [Abstract][Full Text] [Related]
33. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
[TBL] [Abstract][Full Text] [Related]
34. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Therneau TM; Kyle RA; Greipp PR; Gertz MA
Am J Hematol; 2001 Dec; 68(4):269-75. PubMed ID: 11754416
[TBL] [Abstract][Full Text] [Related]
35. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
[TBL] [Abstract][Full Text] [Related]
36. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
[TBL] [Abstract][Full Text] [Related]
37. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis.
Paiva B; Vídriales MB; Pérez JJ; López-Berges MC; García-Sanz R; Ocio EM; de Las Heras N; Cuello R; García de Coca A; Pardal E; Alonso J; Sierra M; Bárez A; Hernández J; Suárez L; Galende J; Mateos MV; San Miguel JF
Blood; 2011 Mar; 117(13):3613-6. PubMed ID: 21266717
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
[TBL] [Abstract][Full Text] [Related]
39. Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma.
Narita K; Kobayashi H; Abe Y; Kitadate H; Takeuchi M; Matsue K
Int J Hematol; 2018 Oct; 108(4):371-374. PubMed ID: 29978432
[TBL] [Abstract][Full Text] [Related]
40. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support.
Boccadoro M; Omedé P; Dominietto A; Palumbo A; Bringhen S; Giaretta F; Ortolano B; Triolo S; Pileri A
Bone Marrow Transplant; 2000 Jan; 25(1):25-9. PubMed ID: 10654010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
